Health Tips

August 31, 2010

A.M. Vitals: Genzyme Points to MS Drug As Sign Sanofi Bid is Too Low

Filed under: Health Care — Nancy @ 7:27 am -0700

Also: Most C-sections performed before labor starts; American companies push into Chinese electronic medical record market; investigators looking at health-care credit cards.


from: http://feedproxy.google.com/~r/wsj/health/feed/~3/HZEt4q37rgg/

Related posts:

  1. A.M. Vitals: Sanofi, Genzyme Still Working on Deal Price
    Also: President Obama’s 2012 budget due out today; new 3-D mammography system approved; retirees’ health...
  2. A.M. Vitals: Sanofi-Aventis (Finally!) Will Buy Genzyme
    Also: results for a faster flu-vaccine production method; generic-drug makers want to pay user fees;...
  3. Sanofi-Aventis to Buy Genzyme: The Wrap-Up
    Deconstructing the deal’s CVR; solving Genzyme’s manufacturing problems; avoiding the pitfalls of pharma-biotech deals; Viehbacher’s...
  4. A.M. Vitals: Sanofi’s 2011 Outlook Disappoints Investors
    Also: health insurers’ 2011 outlook; FDA questions cancer drug makers on follow-up studies; Vermont governor...
  5. Sanofi-Aventis to Buy Genzyme: The Wrap-Up
    The prize. (The company, that is, not the gate.) There are a lot of...

Share/Bookmark

No Comments »

No comments yet.

RSS feed for comments on this post. TrackBack URL

Leave a comment

Copyright © 2009 ChinaFinancialNews.com; Powered by WordPress